Skip to main content
SpringerLink
Log in

Molecular docking and 3D QSAR studies of substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as insulin-like growth factor-1 receptor (IGF1R) inhibitors

  • Original Research
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

Insulin-like growth factor-1 receptor (IGF1R) is one of receptor tyrosine kinase that plays a significant role in cancer and has been pursued as drug target for cancer therapy. Molecular docking and comparative molecular field analysis (CoMFA) studies were carried out on the series of substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines IGF1R inhibitors. The conformations of these inhibitors from docking results provided a reliable conformational alignment scheme for 3D QSAR model. Based on these conformations, significant CoMFA model was performed with a leave-one-out cross-validated q 2 of 0.590. The noncross-validated analysis revealed r 2 value of 0.941, F = 34.882, and an estimated standard error of 0.178 with four optimum components. The predictive ability of our model was validated by the testing set with a conventional r 2 value of 0.925. The effective model may be used to design more potent IGF1R inhibitors and predict their activities before synthesis or experimental test.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  • Baxter CA, Murray CW, Clark DE (1998) Flexible docking using Tabu search and an empirical estimate of binding affinity. Proteins 33:367–382

    Article  PubMed  CAS  Google Scholar 

  • Bush BL, Nachbar RB (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587–619

    Article  PubMed  CAS  Google Scholar 

  • Clark MC, Cramer RD, Opdenbosch NV (1989) Validation of the General Purpose Tripose 5.2 Force Field. J Comput Chem 10:982–1012

    Article  CAS  Google Scholar 

  • Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE (2005) Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16:421–439

    Article  PubMed  CAS  Google Scholar 

  • Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11:425–445

    Article  PubMed  CAS  Google Scholar 

  • Gary TW, Robert AM, Robert DH (2010) Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorg Med Chem Lett 10:6067–6071

    Google Scholar 

  • Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron 36:3219–3228

    Article  CAS  Google Scholar 

  • Grothey A, Voigt W, Schober C, Muller T, Dempke W, Schmoll HJ (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 125:166–173

    Article  PubMed  CAS  Google Scholar 

  • Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de-Bono JS (2007) Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res 13:5834–5840

    Article  PubMed  CAS  Google Scholar 

  • Hidalgo M, Tirado GM, Lewis N, Vuky JL, Taylor G, Hayburn JL, Hsu K, Kosh M, Picozzi VJ (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol ASCO Annu Meet Proc abstract# 3520

  • Higano CS, Yu YE, Whiting SH, et al. (2007) A phase I, first in man study of weekly IMC A-12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumours. ASCO annual meeting proceedings Part I. J Clin Oncol 25(18S)(June 20 Suppl):3505

  • Hynes N, Lane H (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  PubMed  CAS  Google Scholar 

  • Li R, Pourpak A, Morris SW (2009) Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52:4981–5004

    Article  PubMed  CAS  Google Scholar 

  • Moreau P, Hulin C, Facon T, Boccadoro M, Mery MD, Deslandes A, Harousseau JL (2007) Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood 110(11):1166 (ASH annual meeting abstracts)

    Google Scholar 

  • Muddassar M, Pasha FA, Chung HW, Yoo KH, Oh CH, Cho SJ (2008) Receptor guided 3D-QSAR: a useful approach for designing of IGF-1R inhibitors. J Biomed Biotechnol 2008:837653

    Article  PubMed  CAS  Google Scholar 

  • Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928

    Article  PubMed  CAS  Google Scholar 

  • Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58:1159–1164

    PubMed  CAS  Google Scholar 

  • Rothenberg M, Poplin E, Sandler A, Rubin E, Fox F, Schwartz J, Vermeulen W, Youssoufian H (2007) Phase I dose escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. AACR meet abstr no. C84

  • Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12

    Article  PubMed  CAS  Google Scholar 

  • Timo H, Ulrich G, Henning B, Andree B, Adam S (2010) Allosteric IGF-1R inhibitors. Med Chem Lett 1:199–203

    Article  Google Scholar 

  • Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L, Young F, Hwang Y, Haqq C, Puzanov I (2009) Phase I pharmacokinetic and pharmacodynamics study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800–5807

    Article  PubMed  CAS  Google Scholar 

  • Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079–3083

    PubMed  CAS  Google Scholar 

  • Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609–623

    Article  PubMed  CAS  Google Scholar 

  • Werner H, LeRoith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68:183–223

    Article  PubMed  CAS  Google Scholar 

  • Yuli W, Yi S (2002) Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2:191–207

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Zhaoyun Liu for critical evaluation of the manuscript.

Author information

Authors and Affiliations

  1. College of Chemical Engineering, Sichuan University, Chengdu, 610065, Sichuan, China

    Yu-Sheng Li, Lu Zhou & Xiang Ma

Authors
  1. Yu-Sheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiang Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lu Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, YS., Zhou, L. & Ma, X. Molecular docking and 3D QSAR studies of substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as insulin-like growth factor-1 receptor (IGF1R) inhibitors. Med Chem Res 21, 3301–3311 (2012). https://doi.org/10.1007/s00044-011-9877-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-011-9877-9

Keywords

Search

Navigation